Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19312128 | 0.83 | RIPK1 (0.49) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL17724417 | 0.83 | RIPK1 (0.49) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL14018489 | 0.83 | LMNA (0.52) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL25167086 | 0.78 | KIF11 (0.46) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL6305996 | 0.78 | KIF11 (0.46) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL26363857 | 0.78 | RIPK1 (0.52) | RIPK1MAPK1AOC3SLC6A3 | |
| SCHEMBL6689030 | 0.77 | LMNA (0.58) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL1154790 | 0.77 | LMNA (0.58) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| Benzene SCHEMBL27821286 | 0.77 | LMNA (0.58) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL4416648 | 0.77 | LMNA (0.58) | RIPK1LMNAKDM4EL3MBTL1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | RIPK1 610/4885LMNA 4813/4885KDM4E 159/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | RIPK1 610/4885LMNA 4813/4885KDM4E 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.